Innodata Inc vs Revolution Medicines Inc. Common Stock — how do they compare? Innodata Inc trades at $62.2 (market cap $2.10B), while Revolution Medicines Inc. Common Stock trades at $189.32 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 19.2× Innodata Inc's market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| INOD | RVMD | |
|---|---|---|
Market Cap | $2.10B | $40.32B |
Volume | 989,493 | 4,855,734 |
Sector | Technology | Health |
52-Week High | $121.50 | $221.15 |
52-Week Low | $34.45 | $47.50 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | $1.86B | $37.02B |
Signals from Pluang's Aura AI — not financial advice
INOD trades at $62.04, down 2.17% today, amid a bearish technical signal from moving averages. The company shows strong fundamentals with recent earnings beats, including Q2 2026 EPS of $0.41 versus $0.213 expected, and robust profitability with a 14.66% net income margin. Positive news highlights expansion into motion-capture AI labs and strategic board appointments, supporting growth in AI data services.
Outlook remains positive given earnings momentum and AI sector tailwinds, but risks include high valuation multiples like a P/E of 47.43 and customer concentration. Analyst consensus is bullish with 4 buy ratings, suggesting potential upside if execution continues.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →